SCHEMBL4487336

SCHEMBL4487336

CCN(C(=O)/C(C#N)=C/C=C/c1ccc(OC)c(OC)c1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
PKM P14618 1/20 0.47
HTT P42858 1/20 0.47
CYP1A2 P05177 2/20 0.46
MCL1 Q07820 1/20 0.44
APP P05067 2/20 0.43
MAOB P27338 2/20 0.43
BCHE P06276 1/20 0.43
MAOA P21397 1/20 0.43
ACHE P22303 1/20 0.43
SLC16A3 O15427 1/20 0.43
SLC16A1 P53985 1/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP1A1 P04798 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4483001 0.90 KMT2A (0.46) ALDH1A1PKMMCL1SLC16A3SLC16A1
SCHEMBL4486790 0.82 KMT2A (0.45) ALDH1A1PKMMCL1SLC16A3SLC16A1
SCHEMBL9360860 0.80 CYP1A2 (0.59) ALDH1A1PKMHTTCYP1A2MCL1
SCHEMBL9360863 0.80 CYP1A2 (0.59) ALDH1A1PKMHTTCYP1A2MCL1
SCHEMBL4484514 0.76 MAOB (0.70) ALDH1A1PKMCYP1A2MCL1MAOB
SCHEMBL4484519 0.76 MAOB (0.70) ALDH1A1PKMCYP1A2MCL1MAOB
SCHEMBL4487344 0.75 MAOB (0.71) ALDH1A1PKMCYP1A2MCL1MAOB
SCHEMBL6028906 0.75 MAOB (0.71) ALDH1A1PKMCYP1A2MCL1MAOB
SCHEMBL7204107 0.74 MAPT (0.42) ALDH1A1PKMCYP1A2KDM4EHPGD
SCHEMBL4487339 0.73 KMT2A (0.74) ALDH1A1PKMHTTCYP1A2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598419-B2 Compounds for modulating cell proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2009-10-06 US disclosed
US-20070243612-A1 Novel Compounds for Modulating Cell Proliferation HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2007-10-18 US disclosed
EP-1727822-A4 NOVEL COMPOUNDS FOR MODULATING CELL PROLIFERATION HSC RES DEV LP (CA) 2007-05-09 EP disclosed
EP-1727822-A1 NOVEL COMPOUNDS FOR MODULATING CELL PROLIFERATION HSC Research and Development Limited Partnership (CA) 2006-12-06 EP disclosed
WO-2005092904-A1 NOVEL COMPOUNDS FOR MODULATING CELL PROLIFERATION HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2005-10-06 WO disclosed
US-6800659-B2 NOVEL STYRYLACRYLONITRILE COMPOUNDS WHICH ARE USEFUL IN TREATING A VARIETY OF CELL PROLIFERATIVE DISORDERS SUCH AS CANCER ARE DISCLOSED. A METHOD OF MODULATING CELL PROLIFERATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2004-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070243612-A1 Novel Compounds for Modulating Cell Proliferation MKI67, CCNA1, PCNA ALDH1A1 546/4885PKM 2760/4885HTT 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.